ClinicalTrials.gg
CompletedNCT01894919Updated Nov 30, 2021Results posted

Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28

A Phase 3 interventional study of Bexsero® vaccine (1 dose at study month zero) and Bexsero® vaccine (2 doses 1 month apart) in Meningoccocal Disease and Meningococcal Meningitis, sponsored by Novartis Vaccines. Completed at 17 sites in 2 countries. Open to participants aged 35 Months to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-30.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
851
Allocation
Randomized
Ages
35 Months to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Meningitis, Meningococcal by Novartis — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Novartis.

Enrollment
11th of 30
851 · median 707
Started
2013
with 1 other
Phase 3
19 of 32
none open now
Registered
31st of 32
by date

Among the 32 studies in Meningitis, Meningococcal by Novartis, this one is the 11th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2013, is one of 19 in phase 3, and was the 31st registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 32 studies in Meningitis, Meningococcal by Novartis is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 35 Months to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 32 studies in Meningitis, Meningococcal by Novartis as a file.
02

Study summary

The aim of this extension study is to explore the antibody persistence 24 to 36 months after the last dose of vaccine, in infants that received a two or three dose primary series plus a booster dose at 11 months of age, of the Novartis meningococcal B vaccine (Bexsero®) in groups I to III of the parent V72_28 study.

This study will also explore the antibody persistence 24 to 36 months after two catch-up doses of the Novartis meningococcal B vaccine (Bexsero®) administered in children (2 to 10 years old) in group IV of the parent V72_28 study.

03

Conditions studied

  • Meningoccocal Disease
  • Meningococcal Meningitis

Keywords

  • Meningococcal B disease,
  • Antibody persistence
04

Who can participate

Ages eligible
35 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For naïve subjects newly enrolled:

  1. Healthy infants and children according to the following age groups:

    1. Healthy subjects from 35 to 47 months of age, (only applicable to group K) (The age window is defined as the first day the subject turns 35 months of age up to the day before the subject turns 48 months of age),
    2. Healthy subjects 4 to 7 years of age (only applicable to group L) (The age window is defined as the first day the subject turns 4 years of age up to the day before the subject turns 8 years of age).
    3. Healthy subjects 8 to 12 years of age (only applicable to group M) (The age window is defined as the first day the subject turns 8 years of age up to the day before the subject turns 13 years of age).
  2. for whom a parent/legal guardian has given written after the nature of the study has been explained;
  3. for whom a parent/legal guardian confirmed availability for the visit scheduled in the study;
  4. in good health as determined by medical history, physical examination, clinical judgment of the investigator.

For Subjects who participated in the V72_28 study (Follow-on Subjects):

  1. for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;
  2. for whom a parent/legal guardian confirmed availability for the visit scheduled in the study;
  3. in good health as determined by medical history, physical examination, clinical judgment of the investigator
  4. who have completed the vaccination course in the V72_28 study and have received their last vaccination 24 to 36 months before enrollment in V72_28E1

Exclusion criteria

Exclusion Criteria:

For naïve subjects newly enrolled:

  1. History of any serogroup B meningococcal vaccine administration;
  2. Previous known or suspected disease caused by N. meningitidis;
  3. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization;
  4. History of severe allergic reaction after previous vaccinations or to any component of the vaccine;
  5. Pregnancy or nursing (breastfeeding) mothers;
  6. Females of childbearing age who have not used or do not plan to use acceptable measures, for the duration of the study. Oral, injected or implanted hormonal contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine device, surgical sterilization, transdermal delivery, congenital sterility or sexual abstinence are considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods at least two months prior to study entry;
  7. Known or suspected disease or impairment/alteration of the immune system resulting from (for example):

    • Receipt of any chronic therapy
    • Receipt of any chronic immunostimulants
    • Immune deficiency disorder, or known infection
  8. History of seizure, any progressive neurological disease or Guillain Barré Syndrome (exception: one self-limited febrile seizure is acceptable).
  9. Known bleeding diathesis or any condition that may be associated with a prolonged bleeding time.
  10. Subject's parent(s) or legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.
  11. Intent to participate in another clinical study during this study.
  12. Family members and household members of study staff;
  13. History or any illness/condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or pose additional risk to the subjects due to participation in the study.
  14. Any significant chronic infection.
  15. Any serious chronic or progressive disease according to judgment of the investigator (e.g. neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).

For Subjects who participated in the V72_28 study (Follow-on Subjects):

Exclusion criteria are the same as for naïve subjects, with the exception of criterion 1.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
851 participants (actual)

Study arms

  • Experimental
    2H3H511_V

    In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.

    Biological: Bexsero® vaccine (1 dose at study month zero)

  • No intervention
    2H3H511_NV

    In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.

  • Experimental
    3H5_11_V

    In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.

    Biological: Bexsero® vaccine (1 dose at study month zero)

  • No intervention
    3H5_11_NV

    In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.

  • Experimental
    68_11_V

    In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.

    Biological: Bexsero® vaccine (1 dose at study month zero)

  • No intervention
    68_11_NV

    In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.

  • Experimental
    02_2_5_V

    In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.

    Biological: Bexsero® vaccine (1 dose at study month zero)

  • No intervention
    02_2_5_NV

    In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.

  • Experimental
    02_6_10_V

    In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.

    Biological: Bexsero® vaccine (1 dose at study month zero)

  • No intervention
    02_6_10_NV

    In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.

  • Experimental
    NAIVE 123

    Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.

    Biological: Bexsero® vaccine (2 doses 1 month apart)

  • Experimental
    NAIVE_4A

    Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.

    Biological: Bexsero® vaccine (2 doses 1 month apart)

  • Experimental
    NAIVE_4B

    Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.

    Biological: Bexsero® vaccine (2 doses 1 month apart)

Interventions

  • BiologicalBexsero® vaccine (1 dose at study month zero)
  • BiologicalBexsero® vaccine (2 doses 1 month apart)
06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains

    The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules, is presented in terms of the percentage of subjects in each vaccine group, with hSBA titers ≥ 4 for what concerns the H44/76, 5/99 and NZ98/254 strains, and hSBA titers ≥ 5 for M10713 strain, alongside with the corresponding antibody responses in age-matched vaccine naïve subjects at baseline. The functional bactericidal antibodies directed against serogroup B meningococcal were assessed by the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA).

    Time frame: 24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects

  2. Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis Serogroup B Strains

    The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules is presented in terms of the percentage of subjects in each vaccine group with hSBA titers ≥ 8, alongside with the corresponding antibody responses in age matched vaccine naïve subjects at baseline.

    Time frame: At 24-36 months after booster dose in the parent study: baseline for vaccine-naïve subjects

  3. The hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains

    The hSBA antibody titers in subjects, 24 to 36 months after completion of Bexsero® vaccination course according to different schedules in the parent study, are presented in terms of vaccine-group-specific GMTs, alongside with the corresponding antibody responses in age-matched vaccine-naïve subjects at baseline.

    Time frame: 24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects

  4. The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus 1 Month After Completion of Bexsero® Vaccination Course According to Different Schedules in the Parent Study.

    The within-subjects GMR of GMTs at 24 to 36 months versus 1 month after completion of Bexsero® vaccination course according to different schedules vaccination in parent study are reported.

    Time frame: At Day 1 in this study over one month after the completion of the vaccination course in the parent study

  5. The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus Visit 1 in the Parent Study.

    The within-subjects GMR of GMTs at 24 to 36 months versus visit 1 in the vaccination course according to different schedules vaccination in the parent study are reported.

    Time frame: At Day 1 in this study over visit 1 in the vaccination course in the parent study

Secondary outcomes

  1. Percentage of Subjects With hSBA Titers ≥4 or ≥ 5 Against N.Meningitidis Serogroup B, After Receiving Bexsero® Booster Vaccination in This Study.

    The percentage of subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and with hSBA titers ≥ 5 against M10713 strain, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study), alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.

    Time frame: At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)

  2. Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis serogroupB, After Receiving Bexsero® Booster Vaccination in This Study.

    The percentage of subjects with hSBA titers ≥ 8, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.

    Time frame: At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)

  3. Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Bexsero® Vaccination in This Study.

    The percentage of subjects with a four-fold rise in hSBA titers 1 month after receiving Bexsero® booster vaccination in this study to pre vaccination at visit 1 (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.

    Time frame: One month after booster vaccination (day 31)/24-36 months (Visit 1)

  4. Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study

    The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination (visit 2) in this study to post primary visit in the parent study V72_28(1 month after last vaccination in the parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.

    Time frame: From post primary visit in the parent study to visit 2 in this extension study

  5. Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study.

    The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination in this study to pre primary visit in parent study V72_28 (Visit 1). This outcome measure was analysed only for subjects belonging to groups 02_2_5_V and 02_6_10_V

    Time frame: From pre primary visit in the parent study (Visit 1) to visit 2 in this extension study

  6. The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.

    The hSBA antibody titers in subjects after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the 1st dose of Bexsero® vaccine in age matched vaccine-naïve subjects in terms of GMTs.

    Time frame: At Visit 1 and one month post booster vaccination (Day 31)

  7. The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.

    The within-subjects GMR of hSBA antibody titers (one month post booster vaccination versus pre vaccination) after Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the within-subject GMR for the 1st dose of rMenB+OMV NZ vaccination of age matched naïve subjects.

    Time frame: At Day 31 versus Day 1

  8. The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.

    The within-subjects GMR of hSBA antibody titers (one month post booster vaccination in this study versus 1 month post last vaccination visit (post-primary vaccination visit) in parent study V72_28.

    Time frame: Visit 2 (day 31 in extension study) versus post primary vaccination visit in parent study

  9. Percentage of Subjects With hSBA Titers ≥ 4 or ≥ 5, After Receiving Two Catch up Doses of Bexsero® Vaccination

    The percentage of vaccine-naïve subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and ≥ 5 against M10713 strain, one month after receiving two catch up doses of Bexsero® booster vaccination in this study.

    Time frame: At Baseline and One month post second vaccination (Day 61)

  10. Percentage of Subjects With hSBA Titers ≥ 8 , After Receiving Two Catch up Doses of Bexsero® Vaccination.

    The percentage of vaccine-naïve subjects with hSBA titers ≥8, one month after receiving two catch up doses of Bexsero® booster vaccination in this study are reported.

    Time frame: At Baseline and One month post second vaccination (Day 61)

  11. Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Two Catch up Doses of Bexsero® Vaccination.

    The percentage of vaccine-naïve subjects with a four-fold rise in hSBA titers from baseline, one month after receiving two catch up doses of Bexsero® booster vaccination in comparison to prevaccination in this study are reported.

    Time frame: One month post second vaccination (Day 61)

  12. The GMTs in Subjects Who Received Two Catch up Doses of Bexsero® Vaccination.

    The hSBA antibody titers in vaccine-naïve subjects , after receiving two catch up doses of Bexsero® vaccination in this study, are reported in terms of GMTs.

    Time frame: At Baseline and One month post second vaccination (Day 61)

  13. The GMRs of hSBA Titers After Two Catch up Doses of Bexsero® Vaccination Versus hSBA Titers at Baseline.

    The within-subject GMRs of hSBA titers at one month after receiving the second catch up dose to hSBA titers at baseline, for naïve subjects who received two catch up doses of Bexsero® vaccination in this study are reported.

    Time frame: At one month after receiving second vaccination (Day 61) versus baseline (Day 1)

  14. Number of Subjects (35 Months to 7 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.

    The number of subjects (35 months to 7 years of age) with solicited local and systemic adverse events after receiving Bexsero® booster vaccine in the present study.

    Time frame: From day 1 (6 hr) through day 7 after vaccination

  15. Number of Newly Recruited Subjects (Aged 35 Months to 7 Years) Reporting Solicited Local and Systemic Adverse Events After Receiving Catch-up Doses of Bexsero® Vaccine.

    The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.

    Time frame: From day 1 (6 hr) through day 7 after vaccination

  16. Number of Subjects (8 to 12 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.

    Number of subjects (8 to 12 years of age) reporting solicited local and systemic adverse events after receiving Bexsero® booster vaccine.

    Time frame: From day 1 (6 hr) through day 7 after vaccination

  17. Number of Newly Recruited naïve Subjects (Aged 8 to 12 Years of Age) Solicited Local and Systemic Adverse Events After Receiving Bexsero® Vaccine.

    The number newly recruited naïve subjects (aged 8 to12 years of age) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.

    Time frame: From day 1(6 hr) through day 7 after vaccination

  18. Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination.

    The number of subjects reporting unsolicited adverse events after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) or two cach up schedule of Bexsero® vaccine is reported.

    Time frame: From day 1 through day 7 after any vaccination

  19. Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs), Medically Attended AEs and AEs Leading to Withdrawal for Entire Study Period.

    The number of subjects reporting unsolicited SAEs, medically attended AEs and AEs leading to withdrawal after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in the parent study) or two catch-up schedule of Bexsero® vaccine is reported.

    Time frame: Throughout the entire study period (up to 2 months)

07

Results

Posted Dec 7, 2018

Participant flow

Subjects were recruited from 9 study sites in Hungary and 8 study sites in Spain.

Participant flow — Overall Study
Milestone2H3H511_V2H3H511_NV3H5_11_V3H5_11_NV68_11_V68_11_NV02_2_5_V02_2_5_NV02_6_10_V02_6_10_NVNAIVE 123NAIVE_4ANAIVE_4B
Started984789438139323691901005550
Completed96478943783932369189985550
Not completed2000300001200
Withdrew: Withdrawal by subject1000100001100
Withdrew: Adverse event0000000000100
Withdrew: Other-unspecified1000000000000
Withdrew: Lost to follow-up0000200000000

Outcome measures

PrimaryPercentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains

The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules, is presented in terms of the percentage of subjects in each vaccine group, with hSBA titers ≥ 4 for what concerns the H44/76, 5/99 and NZ98/254 strains, and hSBA titers ≥ 5 for M10713 strain, alongside with the corresponding antibody responses in age-matched vaccine naïve subjects at baseline. The functional bactericidal antibodies directed against serogroup B meningococcal were assessed by the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA).

Time frame:
24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains
Percentage of subjects2H3H5113H5_1168_11NAIVE 12302_2_5NAIVE_4A02_6_10NAIVE_4B
H44/7651 (42.8 to 60)53 (43.8 to 61.5)61 (52 to 70.1)38 (28.5 to 48.3)52 (39.7 to 64.6)27 (16.1 to 41)58 (50.3 to 65.2)20 (10 to 33.7)
5/9984 (77.2 to 89.9)88 (80.9 to 92.9)93 (87.2 to 97.1)3 (0.6 to 8.5)79 (67.4 to 88.1)4 (0.44 to 12.5)85 (79.4 to 90.3)8 (2.2 to 19.2)
NZ98/25445 (36.6 to 53.6)38 (29.8 to 47.1)56 (46.9 to 65.4)2 (0.24 to 7)29 (19 to 41.7)7 (2 to 17.6)50 (42.2 to 57.3)6 (1.3 to 16.5)
M1071331 (22.8 to 39.5)36 (27.1 to 45.7)39 (29.4 to 48.3)37 (26.8 to 47.2)34 (22.6 to 46.6)38 (24.8 to 52.1)61 (53.0 to 68.0)55 (40.2 to 69.3)
PrimaryPercentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis Serogroup B Strains

The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules is presented in terms of the percentage of subjects in each vaccine group with hSBA titers ≥ 8, alongside with the corresponding antibody responses in age matched vaccine naïve subjects at baseline.

Time frame:
At 24-36 months after booster dose in the parent study: baseline for vaccine-naïve subjects
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis Serogroup B Strains
Percentage of subjects2H3H5113H5_1168_11NAIVE 12302_2_5NAIVE_4A02_6_10NAIVE_4B
H44/7628 (20.6 to 36.1)26 (18.7 to 34.3)32 (23.7 to 41.1)18 (11 to 26.9)24 (14.3 to 35.9)16 (7.8 to 28.8)34 (26.8 to 41.2)10 (3.3 to 21.8)
5/9980 (72.4 to 86.3)82 (74.8 to 88.5)89 (82 to 94.1)2 (0.24 to 7)73 (60.9 to 83.2)4 (0.44 to 12.5)66 (59.1 to 73.3)6 (1.3 to 16.5)
NZ98/25421 (14.9 to 29.2)18 (12.1 to 26)29 (20.7 to 37.6)0 (0 to 3.6)15 (7.3 to 25.4)2 (0.05 to 9.7)28 (21.5 to 35.1)0 (0 to 7.1)
M1071324 (16.5 to 32)22 (14.4 to 30.4)28 (20.2 to 37.9)26 (17.3 to 35.9)31 (19.9 to 43.4)36 (23.1 to 50.2)54 (46 to 61.4)49 (34.4 to 63.7)
PrimaryThe hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains

The hSBA antibody titers in subjects, 24 to 36 months after completion of Bexsero® vaccination course according to different schedules in the parent study, are presented in terms of vaccine-group-specific GMTs, alongside with the corresponding antibody responses in age-matched vaccine-naïve subjects at baseline.

Time frame:
24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
Reported as:
Geometric mean · Titers
The hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains
Titers2H3H5113H5_1168_11NAIVE 12302_2_5NAIVE_4A02_6_10NAIVE_4B
H44/764.17 (3.4 to 5.13)4.48 (3.6 to 5.57)5.62 (4.48 to 7.04)2.79 (2.25 to 3.45)3.97 (2.99 to 5.28)2.33 (1.77 to 3.07)5.75 (4.78 to 6.91)1.93 (1.39 to 2.68)
5/9944 (32 to 60)52 (37 to 72)83 (58 to 117)1.15 (1.03 to 1.29)21 (14 to 33)1.2 (0.96 to 1.51)21 (16 to 28)1.38 (1.1 to 1.73)
NZ98/2543.48 (2.78 to 4.36)2.98 (2.35 to 3.78)4.86 (3.8 to 6.22)1.14 (1.06 to 1.22)2.81 (2.07 to 3.82)1.37 (1.17 to 1.61)4.57 (3.74 to 5.59)1.22 (1.06 to 1.41)
M107132.77 (2.06 to 3.71)3.03 (2.2 to 4.16)3.17 (2.3 to 4.38)3.3 (2.52 to 4.32)3.53 (2.38 to 5.25)4.26 (2.61 to 6.97)7.82 (6.04 to 10)6.95 (4.18 to 12)
PrimaryThe Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus 1 Month After Completion of Bexsero® Vaccination Course According to Different Schedules in the Parent Study.

The within-subjects GMR of GMTs at 24 to 36 months versus 1 month after completion of Bexsero® vaccination course according to different schedules vaccination in parent study are reported.

Time frame:
At Day 1 in this study over one month after the completion of the vaccination course in the parent study
Reported as:
Geometric mean · Ratio
The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus 1 Month After Completion of Bexsero® Vaccination Course According to Different Schedules in the Parent Study.
Ratio2H3H5113H5_1168_1102_2_502_6_10
H44/760.029 (0.023 to 0.036)0.022 (0.017 to 0.028)0.03 (0.023 to 0.038)0.028 (0.021 to 0.038)0.042 (0.035 to 0.052)
5/990.023 (0.017 to 0.03)0.031 (0.023 to 0.041)0.054 (0.04 to 0.073)0.045 (0.031 to 0.066)0.049 (0.038 to 0.063)
NZ98/2540.059 (0.047 to 0.074)0.038 (0.03 to 0.048)0.07 (0.055 to 0.09)0.061 (0.044 to 0.083)0.095 (0.077 to 0.12)
M107130.19 (0.13 to 0.28)0.16 (0.11 to 0.25)0.19 (0.12 to 0.29)0.17 (0.11 to 0.28)0.24 (0.17 to 0.32)
PrimaryThe Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus Visit 1 in the Parent Study.

The within-subjects GMR of GMTs at 24 to 36 months versus visit 1 in the vaccination course according to different schedules vaccination in the parent study are reported.

Time frame:
At Day 1 in this study over visit 1 in the vaccination course in the parent study
Reported as:
Geometric mean · Ratio
The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus Visit 1 in the Parent Study.
Ratio02_2_502_6_10
H44/761.88 (1.32 to 2.69)2.94 (2.33 to 3.71)
5/9920 (12 to 32)14 (10 to 20)
NZ98/2542.48 (1.76 to 3.49)3.06 (2.44 to 3.83)
M107130.89 (0.49 to 1.61)0.94 (0.64 to 1.37)
SecondaryPercentage of Subjects With hSBA Titers ≥4 or ≥ 5 Against N.Meningitidis Serogroup B, After Receiving Bexsero® Booster Vaccination in This Study.

The percentage of subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and with hSBA titers ≥ 5 against M10713 strain, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study), alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.

Time frame:
At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥4 or ≥ 5 Against N.Meningitidis Serogroup B, After Receiving Bexsero® Booster Vaccination in This Study.
Percentage of subjects2H3H511_V3H5_11_V68_11_V02_2_5_V02_6_10_VNAIVE 123NAIVE_4ANAIVE_4B
H44/76 (pre-vacc.)48 (37.3 to 58.5)51 (40.1 to 62.1)64 (52.1 to 74.8)39 (21.8 to 57.8)59 (48.5 to 69.5)39 (28.8 to 49)27 (16.1 to 41)20 (10 to 33.7)
H44/76 (post-vacc.)99 (94.3 to 99.97)100 (95.8 to 100)100 (95.2 to 100)97 (83.8 to 99.92)99 (94 to 99.97)95 (88.3 to 98.3)91 (80 to 97)80 (66.3 to 90)
5/99 (pre-vacc.)84 (74.5 to 90.6)91 (82.7 to 95.9)95 (87.1 to 98.5)74 (55.4 to 88.1)86 (76.8 to 92.2)3 (0.6 to 8.9)4 (0.44 to 12.5)8 (2.2 to 19.2)
5/99 (post-vacc.)99 (94.3 to 99.97)99 (93.8 to 99.97)97 (90.8 to 99.68)100 (89.1 to 100)100 (96 to 100)88 (79.2 to 93.4)93 (82.4 to 98)80 (66.3 to 90)
NZ98/254 (pre-vacc.)45 (34.2 to 55.3)42 (31.3 to 53)52 (40.2 to 63.7)25 (11.5 to 43.4)47 (36.7 to 58)2 (0.25 to 7.3)7 (2.1 to 17.9)6 (1.3 to 16.5)
NZ98/254 (post-vacc.)99 (94.3 to 99.97)100 (95.8 to 100)100 (95.2 to 100)100 (89.1 to 100)100 (96 to 100)78 (68.5 to 85.9)85 (72.9 to 93.4)70 (55.4 to 82.1)
M10713 (pre-vacc.)36 (25.3 to 47.6)35 (24.1 to 47.8)45 (32.3 to 57.5)21 (8 to 39.7)63 (52.2 to 73.3)39 (28.8 to 50.5)41 (27 to 55.8)59 (43.2 to 73)
M10713 (post-vacc.)70 (59.8 to 79.7)81 (70.6 to 89)97 (89.6 to 99.64)97 (77.9 to 99.2)96 (88.9 to 98.8)47 (35.9 to 57.5)59 (44.2 to 72.4)60 (44.3 to 73.6)
SecondaryPercentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis serogroupB, After Receiving Bexsero® Booster Vaccination in This Study.

The percentage of subjects with hSBA titers ≥ 8, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.

Time frame:
At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis serogroupB, After Receiving Bexsero® Booster Vaccination in This Study.
Percentage of subjects2H3H511_V3H5_11_V68_11_V02_2_5_V02_6_10_VNAIVE 123NAIVE_4ANAIVE_4B
H44/76 (pre-vacc.)26 (17.5 to 36.3)31 (21.8 to 42.3)33 (22.9 to 45.2)19 (7.5 to 37.5)30 (20.5 to 40.2)18 (10.7 to 26.8)16 (7.8 to 28.8)10 (3.3 to 21.8)
H44/76 (post-vacc.)97 (91.1 to 99.4)98 (91.9 to 99.72)99 (92.8 to 99.97)97 (83.8 to 99.92)97 (90.7 to 99.3)68 (57.4 to 76.9)71 (57.1 to 82.4)60 (45.2 to 73.6)
5/99 (pre-vacc.)79 (69.6 to 87.1)85 (75.8 to 91.8)91 (81.9 to 96.2)71 (52 to 85.8)68 (57.5 to 77.5)2 (0.25 to 7.3)4 (0.44 to 12.5)6 (1.3 to 16.5)
5/99 (post-vacc.)99 (94.3 to 99.97)99 (93.8 to 99.97)97 (90.8 to 99.68)100 (89.1 to 100)100 (96 to 100)77 (67.4 to 85)78 (65 to 88.2)60 (45.2 to 73.6)
NZ98/254 (pre-vacc.)22 (13.8 to 31.6)19 (11 to 28.4)28 (18.2 to 39.6)13 (3.5 to 29)26 (17.7 to 36.7)0 (0 to 3.8)2 (0.05 to 9.9)0 (0 to 7.1)
NZ98/54 (post-vacc.)97 (91.1 to 99.4)98 (91.9 to 99.72)100 (95.2 to 100)97 (83.8 to 99.92)97 (90.7 to 99.3)34 (25 to 44.8)54 (39.6 to 67.4)40 (26.4 to 54.8)
M10713 (pre-vacc.)28 (18.6 to 39.5)22 (12.9 to 33.8)34 (22.6 to 46.6)17 (5.8 to 35.8)55 (44.1 to 65.9)27 (18.2 to 38.2)39 (25.2 to 53.8)52 (36.9 to 67.1)
M10713 (post-vacc.)64 (52.7 to 73.6)71 (59.6 to 80.6)94 (85.4 to 98.3)90 (73.5 to 97.9)92 (84.5 to 96.8)34 (24.3 to 45)51 (36.6 to 65.2)57 (42.2 to 71.7)
SecondaryPercentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Bexsero® Vaccination in This Study.

The percentage of subjects with a four-fold rise in hSBA titers 1 month after receiving Bexsero® booster vaccination in this study to pre vaccination at visit 1 (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.

Time frame:
One month after booster vaccination (day 31)/24-36 months (Visit 1)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Bexsero® Vaccination in This Study.
Percentage of subjects2H3H511_V3H5_11_V68_11_V02_2_5_V02_6_10_VNAIVE 123NAIVE_4ANAIVE_4B
H44/76 (Day 31/PRE)95 (87.8 to 98.2)95 (88.5 to 98.7)97 (90.7 to 99.68)94 (78.6 to 99.2)97 (90.7 to 99.3)43 (32.7 to 53.2)53 (38.8 to 66.3)46 (31.8 to 60.7)
5/99 (Day 31/PRE)98 (92.4 to 99.74)98 (91.9 to 99.72)95 (87.1 to 98.5)100 (88.8 to 100)98 (92.3 to 99.73)77 (67.4 to 85)76 (63 to 86.8)60 (45.2 to 73.6)
NZ98/254 (Day 31/PRE)92 (84.9 to 96.9)95 (88.5 to 98.7)93 (85.1 to 97.8)94 (79.2 to 99.2)86 (76.8 to 92.2)34 (25 to 44.8)54 (39.6 to 67.4)40 (26.4 to 54.8)
M10713 (Day 31/PRE)41 (30 to 52.7)50 (37.6 to 62.4)68 (54.9 to 78.8)72 (52.8 to 87.3)53 (41.9 to 63.7)11 (5 to 19.4)20 (10.2 to 34.3)13 (4.9 to 26.3)
SecondaryPercentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study

The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination (visit 2) in this study to post primary visit in the parent study V72_28(1 month after last vaccination in the parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.

Time frame:
From post primary visit in the parent study to visit 2 in this extension study
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study
Percentage of subjects2H3H511_V3H5_11_V68_11_V02_2_5_V02_6_10_V
H44/765 (1.7 to 12.0)5 (1.3 to 11.7)13 (6.6 to 23.2)22 (9.3 to 40.0)17 (9.9 to 26.6)
5/9919 (11.9 to 28.9)27 (17.8 to 37.4)37 (26.1 to 48.7)66 (46.8 to 81.4)72 (61.4 to 80.9)
NZ98/25425 (16.4 to 34.8)15 (8.5 to 25.0)27 (17.6 to 39.1)13 (3.5 to 29.0)18 (10.8 to 27.8)
M1071315 (7.7 to 25.0)21 (11.4 to 33.9)24 (13.1 to 38.2)21 (8.0 to 39.7)11 (5.2 to 20.0)
SecondaryPercentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study.

The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination in this study to pre primary visit in parent study V72_28 (Visit 1). This outcome measure was analysed only for subjects belonging to groups 02_2_5_V and 02_6_10_V

Time frame:
From pre primary visit in the parent study (Visit 1) to visit 2 in this extension study
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study.
Percentage of subjects02_2_5_V02_6_10_V
H44/7697 (83.8 to 99.92)96 (89.1 to 98.8)
5/99100 (89.1 to 100.0)100 (96.0 to 100.0)
NZ98/25494 (78.6 to 99.2)97 (90.6 to 99.3)
M1071367 (46.0 to 83.5)55 (43.5 to 65.9)
SecondaryThe GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.

The hSBA antibody titers in subjects after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the 1st dose of Bexsero® vaccine in age matched vaccine-naïve subjects in terms of GMTs.

Time frame:
At Visit 1 and one month post booster vaccination (Day 31)
Reported as:
Geometric mean · Titers
The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.
Titers2H3H511_V3H5_11_V68_11_V02_2_5_V02_6_10_VNAIVE 123NAIVE_4ANAIVE_4B
The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.3.91 (3.01 to 5.08)4.84 (3.66 to 6.41)6.21 (4.65 to 8.31)3.14 (2.08 to 4.75)6.15 (4.77 to 7.93)2.82 (2.26 to 3.5)2.33 (1.77 to 3.07)1.93 (1.39 to 2.68)
SecondaryThe Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.

The within-subjects GMR of hSBA antibody titers (one month post booster vaccination versus pre vaccination) after Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the within-subject GMR for the 1st dose of rMenB+OMV NZ vaccination of age matched naïve subjects.

Time frame:
At Day 31 versus Day 1
Reported as:
Geometric mean · Ratio
The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.
Ratio2H3H511_V3H5_11_V68_11_V02_2_5_V02_6_10_VNAIVE 123NAIVE_4ANAIVE_4B
H44/76 (Day 31/PRE)41 (30 to 55)43 (31 to 59)46 (33 to 65)50 (31 to 80)42 (31 to 56)4.81 (3.81 to 6.07)7.08 (5.07 to 9.88)6.87 (4.62 to 10)
5/99 (Day 31/PRE)75 (54 to 104)67 (47 to 96)41 (29 to 60)160 (95 to 270)135 (98 to 186)34 (24 to 46)22 (15 to 34)14 (9.11 to 23)
NZ98/254 (Day 31/PRE)28 (20 to 38)29 (21 to 41)27 (19 to 39)24 (15 to 40)18 (13 to 25)6.07 (4.97 to 7.41)9.58 (6.8 to 13)7.01 (4.54 to 11)
M10713 (Day 31/PRE)4.07 (2.8 to 5.91)5.65 (3.77 to 8.47)11 (7.15 to 16)13 (7.29 to 23)6.85 (4.86 to 9.66)1.38 (1.01 to 1.88)2.06 (1.36 to 3.12)1.55 (1.1 to 2.18)
SecondaryThe Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.

The within-subjects GMR of hSBA antibody titers (one month post booster vaccination in this study versus 1 month post last vaccination visit (post-primary vaccination visit) in parent study V72_28.

Time frame:
Visit 2 (day 31 in extension study) versus post primary vaccination visit in parent study
Reported as:
Geometric mean · Ratio
The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.
Ratio2H3H511_V3H5_11_V68_11_V
H44/761.06 (0.82 to 1.38)0.90 (0.68 to 1.20)1.37 (1.02 to 1.84)
5/991.60 (1.20 to 2.13)2.07 (1.52 to 2.82)2.33 (1.69 to 3.20)
NZ98/2541.66 (1.25 to 2.20)1.10 (0.81 to 1.49)1.75 (1.28 to 2.41)
M107131.01 (0.65 to 1.58)1.37 (0.82 to 2.29)2.35 (1.37 to 4.02)
SecondaryPercentage of Subjects With hSBA Titers ≥ 4 or ≥ 5, After Receiving Two Catch up Doses of Bexsero® Vaccination

The percentage of vaccine-naïve subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and ≥ 5 against M10713 strain, one month after receiving two catch up doses of Bexsero® booster vaccination in this study.

Time frame:
At Baseline and One month post second vaccination (Day 61)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥ 4 or ≥ 5, After Receiving Two Catch up Doses of Bexsero® Vaccination
Percentage of subjectsNAIVE 123NAIVE_4ANAIVE_4B
H44/76 (baseline)38 (28.2 to 48.1)26 (15 to 39.7)20 (10.2 to 34.3)
H44/76 (Day 61)100 (96.3 to 100)98 (90.1 to 99.95)100 (92.7 to 100)
5/99 (baseline)3 (0.6 to 8.7)4 (0.45 to 12.7)6 (1.3 to 16.9)
5/99 (Day 61)100 (96.3 to 100)100 (93.4 to 100)100 (92.7 to 100)
NZ98/254 (baseline)2 (0.25 to 7.2)7 (2.1 to 17.9)6 (1.3 to 17.2)
NZ98/254 (Day 61)100 (96.3 to 100)100 (93.4 to 100)100 (92.6 to 100)
M10713 (baseline)34 (24.6 to 45.4)40 (26.4 to 54.8)55 (40.2 to 69.3)
M10713 (Day 61)75 (64.5 to 83.3)69 (54.9 to 81.3)76 (61.1 to 86.7)
SecondaryPercentage of Subjects With hSBA Titers ≥ 8 , After Receiving Two Catch up Doses of Bexsero® Vaccination.

The percentage of vaccine-naïve subjects with hSBA titers ≥8, one month after receiving two catch up doses of Bexsero® booster vaccination in this study are reported.

Time frame:
At Baseline and One month post second vaccination (Day 61)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥ 8 , After Receiving Two Catch up Doses of Bexsero® Vaccination.
Percentage of subjectsNAIVE 123NAIVE_4ANAIVE_4B
H44/76 (baseline)17 (10.4 to 26.3)15 (6.6 to 27.1)10 (3.4 to 22.2)
H44/76 (Day 61)99 (94.4 to 99.97)96 (87.3 to 99.55)98 (89.1 to 99.95)
5/99 (baseline)2 (0.25 to 7.2)4 (0.45 to 12.7)4 (0.5 to 14)
5/99 (Day 61)100 (96.3 to 100)100 (93.4 to 100)98 (89.1 to 99.95)
NZ98/254 (baseline)0 (0 to 3.7)2 (0.05 to 9.9)0 (0 to 7.4)
NZ98/254 (Day 61)96 (89.9 to 98.9)93 (82.1 to 97.9)94 (82.8 to 98.7)
M10713 (baseline)25 (16.6 to 35.7)38 (24.7 to 52.8)49 (34.4 to 63.7)
M10713 (Day 61)65 (54.1 to 74.6)63 (49 to 76.4)69 (54.6 to 81.7)
SecondaryPercentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Two Catch up Doses of Bexsero® Vaccination.

The percentage of vaccine-naïve subjects with a four-fold rise in hSBA titers from baseline, one month after receiving two catch up doses of Bexsero® booster vaccination in comparison to prevaccination in this study are reported.

Time frame:
One month post second vaccination (Day 61)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Two Catch up Doses of Bexsero® Vaccination.
Percentage of subjectsNAIVE 123NAIVE_4ANAIVE_4B
H44/7694 (87.1 to 97.7)89 (77.4 to 95.8)94 (83.1 to 98.7)
5/99100 (96.3 to 100)100 (93.4 to 100)98 (89.1 to 99.95)
NZ98/25494 (87.1 to 97.7)91 (79.7 to 96.9)94 (82.8 to 98.7)
M1071337 (26.7 to 47.8)28 (16.2 to 42.5)22 (11.8 to 36.6)
SecondaryThe GMTs in Subjects Who Received Two Catch up Doses of Bexsero® Vaccination.

The hSBA antibody titers in vaccine-naïve subjects , after receiving two catch up doses of Bexsero® vaccination in this study, are reported in terms of GMTs.

Time frame:
At Baseline and One month post second vaccination (Day 61)
Reported as:
Geometric mean · Titers
The GMTs in Subjects Who Received Two Catch up Doses of Bexsero® Vaccination.
TitersNAIVE 123NAIVE_4ANAIVE_4B
H44/76 (baseline)2.3 (1.75 to 3.01)2.15 (1.55 to 3)1.56 (1.11 to 2.2)
H44/76 (Day 61)107 (84 to 135)74 (56 to 99)63 (47 to 85)
5/99 (baseline)1.13 (0.94 to 1.36)1.13 (0.9 to 1.41)1.31 (1.04 to 1.65)
5/99 (Day 61)631 (503 to 792)421 (319 to 555)317 (238 to 423)
NZ98/254 (baseline)1.11 (0.98 to 1.26)1.34 (1.15 to 1.56)1.2 (1.02 to 1.4)
NZ98/254 (Day 61)34 (27 to 42)37 (28 to 49)34 (26 to 46)
M10713 (baseline)2.9 (1.94 to 4.34)4.12 (2.54 to 6.69)6.4 (3.91 to 10)
M10713 (Day 61)12 (7.57 to 18)11 (6.87 to 19)14 (8.34 to 24)
SecondaryThe GMRs of hSBA Titers After Two Catch up Doses of Bexsero® Vaccination Versus hSBA Titers at Baseline.

The within-subject GMRs of hSBA titers at one month after receiving the second catch up dose to hSBA titers at baseline, for naïve subjects who received two catch up doses of Bexsero® vaccination in this study are reported.

Time frame:
At one month after receiving second vaccination (Day 61) versus baseline (Day 1)
Reported as:
Geometric mean · Ratio
The GMRs of hSBA Titers After Two Catch up Doses of Bexsero® Vaccination Versus hSBA Titers at Baseline.
RatioNAIVE 123NAIVE_4ANAIVE_4B
H44/7646 (34 to 63)34 (24 to 50)41 (27 to 60)
5/99558 (423 to 737)373 (266 to 524)242 (171 to 344)
NZ98/25430 (24 to 39)27 (20 to 37)29 (21 to 39)
M107133.86 (2.62 to 5.69)2.93 (1.84 to 4.67)2.2 (1.37 to 3.53)
SecondaryNumber of Subjects (35 Months to 7 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.

The number of subjects (35 months to 7 years of age) with solicited local and systemic adverse events after receiving Bexsero® booster vaccine in the present study.

Time frame:
From day 1 (6 hr) through day 7 after vaccination
Reported as:
Number · Subjects
Number of Subjects (35 Months to 7 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.
Subjects2H3H511_V3H5_11_V68_11_V02_2_5_V
Any local AEs87817331
Erythema60634222
Induration48483315
Swelling49503720
Tenderness84807131
Any systemic AEs66635418
Change in eating habits3132305
Diarrhea4850
Irritability5452469
Persistent Crying3124254
Rash13135
Sleepiness2823265
Vomiting5521
Fever (>38.0° C)1718112
Medically-Attended Fever1020
Prevention of Pain and/or Fever2314151
Treatment of Pain and/or Fever38394113
SecondaryNumber of Newly Recruited Subjects (Aged 35 Months to 7 Years) Reporting Solicited Local and Systemic Adverse Events After Receiving Catch-up Doses of Bexsero® Vaccine.

The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.

Time frame:
From day 1 (6 hr) through day 7 after vaccination
Reported as:
Number · Subjects
Number of Newly Recruited Subjects (Aged 35 Months to 7 Years) Reporting Solicited Local and Systemic Adverse Events After Receiving Catch-up Doses of Bexsero® Vaccine.
SubjectsNAIVE 123NAIVE_4A
Any local AEs (1st vacc.)8855
Erythema (1st vacc.)5428
Induration (1st vacc.)3817
Swelling (1st vacc.)4024
Tenderness (1st vacc.)8755
Any systemic AEs (1st vacc.)6424
Change in Eating Habits (1st vacc.)315
Diarrhea (1st vacc.)43
Irritability (1st vacc.)4016
Persistent Crying (1st vacc.)154
Rash (1st vacc.)53
Sleepiness (1st vacc.)189
Vomiting (1st vacc.)72
Fever (>38.0° C) (1st vacc.)152
Medically-Attended Fever (1st vacc.)10
Prevention of Pain/Fever (1st vacc.)183
Treatment of Pain/Fever (1st vacc.)4122
Any local AEs (2nd vacc.)7951
Erythema (2nd vacc.)4432
Induration (2nd vacc.)2922
Swelling (2nd vacc.)3225
Tenderness (2nd vacc.)7751
Any systemic AEs (2nd vacc.)4618
Change in Eating Habits (2nd vacc.)159
Diarrhea (2nd vacc.)23
Irritability (2nd vacc.)2511
Persistent Crying (2nd vacc.)136
Rash (2nd vacc.)21
Sleepiness (2nd vacc.)125
Vomiting (2nd vacc.)42
Fever (>38.0° C) (2nd vacc.)123
Medically-Attended Fever (2nd vacc.)01
Prevention of Pain/Fever (2nd vacc.)214
Treatment of Pain/Fever (2nd vacc.)3013
SecondaryNumber of Subjects (8 to 12 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.

Number of subjects (8 to 12 years of age) reporting solicited local and systemic adverse events after receiving Bexsero® booster vaccine.

Time frame:
From day 1 (6 hr) through day 7 after vaccination
Reported as:
Number · Subjects
Number of Subjects (8 to 12 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.
Subjects02_6_10_V
Any local AEs85
Erythema57
Induration44
Swelling52
Pain84
Any systemic AEs57
Arthralgia18
Chills23
Headache27
Malaise35
Myalgia24
Nausea12
Rash10
Fever (>38.0° C)10
Medically-Attended Fever0
Prevention of Pain and/or Fever12
Treatment of Pain and/or Fever47
SecondaryNumber of Newly Recruited naïve Subjects (Aged 8 to 12 Years of Age) Solicited Local and Systemic Adverse Events After Receiving Bexsero® Vaccine.

The number newly recruited naïve subjects (aged 8 to12 years of age) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.

Time frame:
From day 1(6 hr) through day 7 after vaccination
Reported as:
Number · Subjects
Number of Newly Recruited naïve Subjects (Aged 8 to 12 Years of Age) Solicited Local and Systemic Adverse Events After Receiving Bexsero® Vaccine.
SubjectsNAIVE_4B
Any local AEs (1st vacc.)49
Erythema (1st vacc.)31
Induration (1st vacc.)19
Swelling (1st vacc.)29
Pain (1st vacc.)47
Any systemic AEs (1st vacc.)24
Arthralgia (1st vacc.)6
Chills (1st vacc.)4
Headache (1st vacc.)15
Malaise (1st vacc.)7
Myalgia (1st vacc.)12
Nausea (1st vacc.)5
Rash (1st vacc.)1
Fever (>38.0° C) (1st vacc.)3
Medically-Attended Fever (1st vacc.)0
Prevention of Pain and/or Fever (1st vacc.)2
Treatment of Pain and/or Fever (1st vacc.)21
Any local AEs (2nd vacc.)43
Erythema (2nd vacc.)21
Induration (2nd vacc.)17
Swelling (2nd vacc.)21
Pain (2nd vacc.)41
Any systemic AEs (2nd vacc.)25
Arthralgia (2nd vacc.)3
Chills (2nd vacc.)5
Headache (2nd vacc.)10
Malaise (2nd vacc.)13
Myalgia (2nd vacc.)8
Nausea (2nd vacc.)4
Rash (2nd vacc.)3
Fever (>38.0° C) (2nd vacc.)1
Medically-Attended Fever (2nd vacc.)0
Prevention of Pain and/or Fever (2nd vacc.)3
Treatment of Pain and/or Fever (2nd vacc.)12
SecondaryNumber of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination.

The number of subjects reporting unsolicited adverse events after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) or two cach up schedule of Bexsero® vaccine is reported.

Time frame:
From day 1 through day 7 after any vaccination
Reported as:
Number · Subjects
Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination.
Subjects2H3H511_V3H5_11_V68_11_V02_2_5_V02_6_10_VNAIVE 123NAIVE_4ANAIVE_4B
Any AEs261926914432512
Possibly or Probably Related AEs971061112106
AEs leading to Premature Withdrawal00000100
SecondaryNumber of Subjects Reporting Unsolicited Serious Adverse Events (SAEs), Medically Attended AEs and AEs Leading to Withdrawal for Entire Study Period.

The number of subjects reporting unsolicited SAEs, medically attended AEs and AEs leading to withdrawal after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in the parent study) or two catch-up schedule of Bexsero® vaccine is reported.

Time frame:
Throughout the entire study period (up to 2 months)
Reported as:
Number · Subjects
Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs), Medically Attended AEs and AEs Leading to Withdrawal for Entire Study Period.
Subjects2H3H511_V3H5_11_V68_11_V02_2_5_V02_6_10_VNAIVE 123NAIVE_4ANAIVE_4B
Any SAEs00000000
Possibly or probably related SAEs00000000

Adverse events

Collected over Solicited and unsolicited AEs were collected from Day 1 (30 minutes) throughout Day 7; SAEs were collected throughout the entire study period (up to 2 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2H3H511_V0/97 (0%)0/97 (0%)91/97 (93.8%)
3H5_11_V0/89 (0%)0/89 (0%)84/89 (94.4%)
68_11_V0/80 (0%)0/80 (0%)75/80 (93.8%)
02_2_5_V0/32 (0%)0/32 (0%)31/32 (96.9%)
02_6_10_V0/91 (0%)0/91 (0%)86/91 (94.5%)
NAIVE 1230/100 (0%)0/100 (0%)97/100 (97%)
NAIVE_4A0/55 (0%)0/55 (0%)55/55 (100%)
NAIVE_4B0/50 (0%)0/50 (0%)50/50 (100%)
Most frequent other events
Showing 10 of 21
Most frequent other events
Event2H3H511_V3H5_11_V68_11_V02_2_5_V02_6_10_VNAIVE 123NAIVE_4ANAIVE_4B
Injection site painGeneral disorders84/9680/8971/7831/3284/9194/10055/5548/50
Injection site erythemaGeneral disorders61/9663/8942/7822/3257/9165/10038/5537/50
Injection site swellingGeneral disorders49/9650/8937/7820/3252/9151/10036/5534/50
IrritabilityPsychiatric disorders54/9652/8946/789/320/9148/10019/551/50
Injection site indurationGeneral disorders48/9648/8933/7815/3244/9148/10028/5525/50
HeadacheNervous system disorders0/960/890/780/3227/910/1001/5520/50
MalaiseGeneral disorders0/960/890/780/3235/910/1000/5516/50
Eating disorderPsychiatric disorders31/9632/8930/785/320/9136/10013/550/50
SomnolenceNervous system disorders28/9623/8926/785/320/9123/10010/550/50
CryingGeneral disorders31/9624/8925/784/320/9123/1008/550/50

Baseline characteristics

Age, Continuous
Age, Continuous(Years)2H3H511_V2H3H511_NV3H5_11_V3H5_11_NV68_11_V68_11_NV02_2_5_V02_2_5_NV02_6_10_V02_6_10_NVNAIVE 123NAIVE_4ANAIVE_4BTotal
Mean3.1 ± 0.23 ± 0.183.1 ± 0.233.1 ± 0.223.2 ± 0.293.2 ± 0.266.5 ± 1.156.7 ± 1.1610.4 ± 1.4310.4 ± 1.443.4 ± 0.295.8 ± 1.129.7 ± 1.385.6 ± 3.20
Sex: Female, Male
Sex: Female, Male(Participants)2H3H511_V2H3H511_NV3H5_11_V3H5_11_NV68_11_V68_11_NV02_2_5_V02_2_5_NV02_6_10_V02_6_10_NVNAIVE 123NAIVE_4ANAIVE_4BTotal
Female44274822352319154446462627422
Male54204121461613214744542923429
08

Study locations

17 sites
  • Site 34, General Pediatric Practice Somorjai
    Debrecen, Bajcsi Ut 32 4025, Hungary
  • Site 35, Praxis Dr Eva Kovacs
    Szeged, Csongradi Sgt 63 6723, Hungary
  • Site 36, General Practice Dr Edit Oszlacs
    Szeged, Debreceni Utca 10-14 6723, Hungary
  • Site 37, Praxis Dr Julianna Kovacs
    Bordany, Honved Utca 2 6795, Hungary
  • Site 31, General Practice Dr Olga Fekete
    Miskolc, Kando Kalman Utca 1 3534, Hungary
  • Site 40, General Pediatric Practice Hacsek
    Budapest, Poth Iren U 80 1188, Hungary
  • Site 30, General Practice Dr Simko
    Miskolc, Selyemret U. 1. 3527, Hungary
  • Site 33, General Pediatric Practice Ujhelyi
    Nyiregyhaza, Szent Istvan U 10 4400, Hungary
  • Site 42, Praxis Dr Eszter Bari
    Csongrad, Szentharomsag Ter 10 6640, Hungary
  • Site 15
    Almeria, 04007, Spain
  • Site 16
    Almeria, 04120, Spain
  • Site 20
    Barcelona, 08195, Spain
  • Site 17
    Madrid, 28041, Spain
  • Site 18
    Madrid, 28935, Spain
  • Site 13
    Pontevedra, 36002, Spain
  • Site 10
    Santiago de Compostela, 15706, Spain
  • Site 14
    Sevilla, 41014, Spain
09

References and documents

Publications

  • Martinon-Torres F, Carmona Martinez A, Simko R, Infante Marquez P, Arimany JL, Gimenez-Sanchez F, Couceiro Gianzo JA, Kovacs E, Rojo P, Wang H, Bhusal C, Toneatto D. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial. J Infect. 2018 Mar;76(3):258-269. doi: 10.1016/j.jinf.2017.12.005. Epub 2017 Dec 15. PubMed 29253560 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Sep 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2018, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jul 10, 2013
Start
Jun 2013
Primary completionActual
Sep 2015
CompletionActual
Nov 2015
Results first posted
Dec 7, 2018
Last update
Nov 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01894919
Lead sponsor
Novartis Vaccines
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 10, 2013
Start date
Jun 2013
Primary completion
Sep 2015
Completion
Nov 2015
Results posted
Dec 7, 2018
Last update
Nov 30, 2021

Study contacts

Novartis Vaccines and Diagnostics
study chair · Novartis Vaccines

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion